CDK4/6 inhibitor-induced colitis: a case report and review of the literature

被引：2
作者：
Malik, Azhar Abbas [1 ]
Abbas, Haider [1 ]
Oo, Zin Mar [1 ]
Lim, Zerlene [1 ]
机构：
[1] Queen Elizabeth Hosp, Med Oncol Dept, Birmingham, W Midlands, England
来源：
BMJ CASE REPORTS | 2021年 / 14卷 / 07期
关键词：
Breast cancer; Unwanted effects; adverse reactions; BREAST-CANCER; ABEMACICLIB; PALBOCICLIB; COMBINATION; LETROZOLE;
D O I：
10.1136/bcr-2021-242766
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A 72-year-old woman with metastatic ER/PR-positive breast cancer who had been on ribociclib and letrozole for 1 year developed severe life-threatening colitis. She presented to emergency department with features of acute abdomen and diarrhoea. The diagnosis of colitis was confirmed radiologically as well as by histopathological examination of the biopsy specimen and the patient clinically improved after withholding ribociclib and receiving corticosteroids compatible with ribociclib-induced colitis. The mechanism of injury in CDK 4/6 inhibitor-induced colitis is unknown but may be related to recruitment of inflammatory cells. Whether the development of colitis is associated with tumour response is an interesting and unanswered question.
引用
收藏
页数：3
相关论文
共 11 条
  • [1] MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
    Dickler, Maura N.
    Tolaney, Sara M.
    Rugo, Hope S.
    Cortes, Javier
    Dieras, Veronique
    Patt, Debra
    Wildiers, Hans
    Hudis, Clifford A.
    O'Shaughnessy, Joyce
    Zamora, Esther
    Yardley, Denise A.
    Frenzel, Martin
    Koustenis, Andrew
    Baselga, Jose
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5218 - 5224
  • [2] Palbociclib and Letrozole in Advanced Breast Cancer
    Finn, Richard S.
    Martin, Miguel
    Rugo, Hope S.
    Jones, Stephen
    Im, Seock-Ah
    Gelmon, Karen
    Harbeck, Nadia
    Lipatov, Oleg N.
    Walshe, Janice M.
    Moulder, Stacy
    Gauthier, Eric
    Lu, Dongrui R.
    Randolph, Sophia
    Dieras, Veronique
    Slamon, Dennis J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) : 1925 - 1936
  • [3] The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
    Finn, Richard S.
    Crown, John P.
    Lang, Istvan
    Boer, Katalin
    Bondarenko, Igor M.
    Kulyk, Sergey O.
    Ettl, Johannes
    Patel, Ravindranath
    Pinter, Tamas
    Schmidt, Marcus
    Shparyk, Yaroslav
    Thummala, Anu R.
    Voytko, Nataliya L.
    Fowst, Camilla
    Huang, Xin
    Kim, Sindy T.
    Randolph, Sophia
    Slamon, Dennis J.
    [J]. LANCET ONCOLOGY, 2015, 16 (01) : 25 - 35
  • [4] MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
    Goetz, Matthew P.
    Toi, Masakazu
    Campone, Mario
    Sohn, Joohyuk
    Paluch-Shimon, Shani
    Huober, Jens
    Park, In Hae
    Tredan, Olivier
    Chen, Shin-Cheh
    Manso, Luis
    Freedman, Orit C.
    Jaliffe, Georgina Garnica
    Forrester, Tammy
    Frenzel, Martin
    Barriga, Susana
    Smith, Ian C.
    Bourayou, Nawel
    Di Leo, Angelo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (32) : 3638 - +
  • [5] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, C. S.
    Paluch-Shimon, S.
    Campone, M.
    Petrakova, K.
    Blackwell, K. L.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D. A.
    Mondal, S.
    Su, F.
    Miller, M.
    Elmeliegy, M.
    Germa, C.
    O'Shaughnessy, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (07) : 1541 - 1547
  • [6] KDIGO Clinical Practice Guidelines for Acute Kidney Injury
    Khwaja, Arif
    [J]. NEPHRON CLINICAL PRACTICE, 2012, 120 (04): : C179 - C184
  • [7] QT-interval prolongation during the treatment with ribociclib and endocrine agents in patients with hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer: A real-world experience
    Kurbacher, Christian M.
    Schott, Alexander
    Kurbacher, Ann T.
    Herz, Susanne
    Fischer, Lotta A.
    Kurbacher, Jutta A.
    Warm, Mathias
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [8] Treating cancer with selective CDK4/6 inhibitors
    O'Leary, Ben
    Finn, Richard S.
    Turner, Nicholas C.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (07) : 417 - 430
  • [9] MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
    Sledge, George W., Jr.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han
    Grischke, Eva-Maria
    Frenzel, Martin
    Lin, Yong
    Barriga, Susana
    Smith, Ian C.
    Bourayou, Nawel
    Llombart-Cussac, Antonio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (25) : 2875 - +
  • [10] Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
    Spring, Laura M.
    Zangardi, Mark L.
    Moy, Beverly
    Bardia, Aditya
    [J]. ONCOLOGIST, 2017, 22 (09) : 1039 - 1048
12